Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

Elena Koundourakis, PhD, head of orexin franchise development at Takeda, talked about the phase 2 trial investigating TAK-994 in patients with narcolepsy type 1, which showed significant improvements in wakefulness, despite discontinuation because of hepatotoxicity.

Novel Insights on Orexin Receptor TAK-994 and its Discontinued Narcolepsy Study 

Videos

The clinical professor of neurology at Lenox Hill Hospital/Northwell Health talked about her experience with monoclonal antibodies for Alzheimer disease treatment as well as the challenges and risks associated with them. [WATCH TIME: 8 minutes] 

Diving Into the Potential of Monoclonal Antibodies for Alzheimer Disease Treatment: Gayatri Devi, MD

After being diagnosed with acute flaccid myelitis more than 10 years ago, patient advocate Sarah Todd Hammer spoke on the ways in which disability should be viewed and discussed.

NeuroVoices: Sarah Todd Hammer on Changing the Perceptions and Conversations on Neurologic Disability

At the conclusion of a 12-weel treatment period, biomarker data provided mechanistic insights of senolytic effects using dasatinib and quercetin that need to be confirmed in fully powered, placebo-controlled studies.

Combination Therapy Demonstrates Ability to Clear Senescent Cells in Alzheimer Disease

The senior vice president and chief scientific officer of the Parkinson’s Foundation provided perspective on the reasons for the lack of mental health specialists in Parkinson disease care and the complexities behind treating depression. [WATCH TIME: 4 minutes]

The Effects of Depression in Parkinson Disease and Need for Mental Health Professionals: James Beck, PhD

, has been with the team since October 2019. Follow him on Twitter 

Professor of neurology, Icahn School of Medicine, and staff neurologist, Corinne Goldsmith Dickinson Center for MS, Mount Sinai

The associate professor of neurology at Icahn School of Medicine at Mount Sinai talked about the promising new treatments for multiple sclerosis, the significance of the spinal cord in the disease, and the use of artificial intelligence in neuroimaging. [WATCH TIME: 3 minutes]

Emerging Trends That Challenge the Landscape of Care for Multiple Sclerosis: Stephen Krieger, MD

The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute provided clarity on the complexities with treating subarachnoid hemorrhage on an individual case basis. [WATCH TIME: 4 minutes]

Treatment Decision Process for Subarachnoid Hemorrhage: Guilherme Dabus, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

MSMilan 2023

NMOSD

Narcolepsy

Parkinson Disease

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

Authors

Jason Freeman, MD, MBA, and Arsalan Syed, PhD, discuss highlights from the session “Multiple Sclerosis Disease Modifying Treatments” presented at AAN 2023.

Sponsored By Novartis

AAN Highlights: Multiple Sclerosis Disease Modifying Treatments